BEXO biologics are supplied to practitioners across four high-interest regenerative medicine indications, each supported by independent peer-reviewed evidence. All products referenced are investigational.
01
Systemic
IV Wellness & Longevity
Intravenous administration of HMSC-derived exosomes represents a systemic regenerative protocol for physician-supervised longevity and integrative medicine practice. Research indicates that exosome cargo - including IL-10, TSG-6, and immunomodulatory microRNA - may interact with systemic inflammatory pathways, offering a cell-free biological approach to age-related functional decline.
Preclinical and early clinical data suggest that intravenous HMSC exosomes may support the reduction of chronic low-grade inflammation, a hallmark of biological ageing. The proposed mechanism involves downregulation of pro-inflammatory cytokine cascades and simultaneous upregulation of anti-inflammatory mediators, contributing to immune recalibration across multiple organ systems.
Emerging research also points to potential effects on cellular senescence signalling and mitochondrial repair pathways. Exosomal miRNA cargo has been associated with the modulation of senescence-associated secretory phenotype (SASP) markers and the restoration of mitochondrial membrane potential in aged cell populations. These pathways are of particular interest to practitioners managing patients with autoimmune conditions, chronic fatigue, and systemic inflammatory disorders.
Non-surgical alopecia protocols using HMSC-derived exosomes are an area of active investigation for dermatologists and trichologists. Research indicates that exosomal cargo may activate the Wnt/β-catenin signalling pathway, a critical regulator of hair follicle cycling and stem cell differentiation within the dermal papilla.
Intradermal delivery of exosome biologics has been associated with multiple regenerative mechanisms in hair biology. Preclinical studies suggest that HMSC exosomes promote angiogenesis within the scalp microvasculature, improving nutrient delivery and oxygenation to hair follicle units. This enhanced vascularisation is proposed to support dermal papilla cell proliferation and extend the anagen (active growth) phase of the hair cycle.
Additionally, the anti-inflammatory cargo profile - including miR-21 and miR-146a - may reduce perifollicular inflammation, a contributing factor in both androgenetic and alopecia areata pathologies. Investigators report improvements in both hair density and shaft diameter across multiple alopecia subtypes, with no serious adverse events documented in published studies.
Wnt/β-catenin pathway activation
Angiogenesis for scalp vascularisation
Dermal papilla cell proliferation
Anagen phase extension
Scalp inflammation reduction
Systematic review 2025 (11 studies, 2 RCTs): 9.5–35 hairs/cm² density gain; up to 13μm thickness improvement across alopecia types. No serious adverse events reported.
HMSC-derived exosomes are under investigation for neurologists and rehabilitation specialists managing post-stroke recovery, traumatic brain injury (TBI), and peripheral nerve repair. Research indicates that exosomal nanovesicles possess the capacity to cross the blood-brain barrier (BBB), a property that distinguishes them from larger cell-based therapies and many conventional pharmaceutical agents.
The neurotrophic cargo profile of HMSC exosomes - including brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) - is proposed to support neuronal survival, axonal growth, and synaptic plasticity in damaged neural tissue. Preclinical models indicate enhancement of endogenous neuroplasticity mechanisms, potentially supporting functional recovery in both central and peripheral nervous system injuries.
Additional mechanisms under investigation include peripheral nerve remyelination, where exosomal signalling may promote Schwann cell differentiation and myelin sheath repair, and anti-inflammatory neuroprotection through microglial polarisation from pro-inflammatory (M1) to anti-inflammatory (M2) phenotypes. These pathways are of particular relevance to post-acute rehabilitation protocols.
Blood-brain barrier penetration
BDNF / GDNF neurotrophic delivery
Neuroplasticity enhancement
Peripheral nerve repair and remyelination
Anti-inflammatory neuroprotection
Nature Reviews Neurology: Investigational evidence indicates that the microRNA cargo of MSC-derived exosomes is responsible for their observed effects on neural repair pathways, representing a promising cell-free approach to neurorecovery.
For pain specialists, orthopaedic physicians, and interventional practitioners, HMSC-derived exosomes represent an investigational biological approach to chronic pain conditions including osteoarthritis, facet-mediated pain, and discogenic pathology. Research indicates that the anti-inflammatory and chondroprotective cargo of HMSC exosomes may address underlying tissue pathology rather than symptom masking alone.
Central to the proposed mechanism is the inhibition of the NF-κB inflammatory signalling pathway, a master regulator of cartilage degradation, synovial inflammation, and pain sensitisation in degenerative joint disease. Exosomal cargo including TSG-6, IL-10, and specific miRNA sequences has been associated with the downregulation of matrix metalloproteinases (MMPs) and protection of articular chondrocytes from apoptosis.
Research also suggests potential applications in neuropathic pain modulation, where exosomal anti-inflammatory mediators may reduce dorsal root ganglion sensitisation. In disc pathology, investigators are exploring the capacity of exosomal growth factors to support nucleus pulposus cell viability and arrest the inflammatory cascade that drives discogenic pain. Synovial fluid analysis in preclinical models indicates measurable reduction in inflammatory cytokine concentrations following intra-articular exosome administration.
NF-κB pathway inhibition
Cartilage chondrocyte protection
Neuropathic pain modulation
Synovial inflammation reduction
Intervertebral disc repair
PMC Clinical Review (2024): 65% BPI severity reduction, 72% interference reduction, 58% ODI improvement at 3 months. Frontiers in Pharmacology (2025): MSC exosomes improve OA healing outcomes across preclinical and early clinical models. Journal of Pain Research (2024): Evidence-based guidelines for facet-mediated and discogenic low back pain management.
All applications described on this page are investigational. No exosome product has received regulatory approval as a therapeutic product by the FDA, EMA, TGA, or any other regulatory authority. BEXO biologics are supplied as research-grade materials. Practitioners assume full clinical and regulatory responsibility for patient administration. For a comprehensive review of the published clinical evidence, see HMSC Exosome Clinical Evidence: A Practitioner Review.
Explore the evidence behind these applications.
Review the peer-reviewed studies and safety data that inform practitioner protocols across all four application areas.